AU2001238612A1 - Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease - Google Patents

Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease

Info

Publication number
AU2001238612A1
AU2001238612A1 AU2001238612A AU3861201A AU2001238612A1 AU 2001238612 A1 AU2001238612 A1 AU 2001238612A1 AU 2001238612 A AU2001238612 A AU 2001238612A AU 3861201 A AU3861201 A AU 3861201A AU 2001238612 A1 AU2001238612 A1 AU 2001238612A1
Authority
AU
Australia
Prior art keywords
screening
treatment
neurodegenerative disease
amyloidogenic properties
amyloidogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238612A
Inventor
Eliezer Masliah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU2001238612A1 publication Critical patent/AU2001238612A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001238612A 2000-02-18 2001-02-20 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease Abandoned AU2001238612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18357100P 2000-02-18 2000-02-18
US60183571 2000-02-18
PCT/US2001/005569 WO2001060794A2 (en) 2000-02-18 2001-02-20 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease

Publications (1)

Publication Number Publication Date
AU2001238612A1 true AU2001238612A1 (en) 2001-08-27

Family

ID=22673379

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238612A Abandoned AU2001238612A1 (en) 2000-02-18 2001-02-20 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease

Country Status (3)

Country Link
US (3) US7276643B2 (en)
AU (1) AU2001238612A1 (en)
WO (1) WO2001060794A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004538013A (en) * 2001-08-20 2004-12-24 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア Development of genetic recombination model for medical treatment of neurodegenerative diseases
US7092584B2 (en) 2002-01-04 2006-08-15 Time Warner Entertainment Company Lp Registration of separations
AT500282A3 (en) * 2002-03-28 2006-06-15 Jsw Res Forschungslabor Gmbh NEUROTROPHIC AND NEUROPROTECTIVE PEPTIDES
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7618948B2 (en) 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2004113535A1 (en) * 2003-06-22 2004-12-29 Koji Sode Synuclein mutant having anticoagulant effect
US7550649B2 (en) 2003-10-30 2009-06-23 Taisho Pharmaceutical Co., Ltd. Transgenic non-human mammal
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
MX2007001679A (en) 2004-08-09 2007-05-23 Elan Pharm Inc Prevention and treatment of synucleinopathic and amyloidogenic disease.
US8502016B1 (en) 2005-02-11 2013-08-06 Elan Pharmaceuticals, Inc. Genomic alpha synuclein transgenic animal
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
US20090010894A1 (en) * 2005-12-23 2009-01-08 The Parkinson's Institute Methods and systems for identifying compounds that modulate alpha-synuclein aggregation
US20070214509A1 (en) * 2005-12-23 2007-09-13 The Parkinson's Institute Methods and systems for identifying compounds that modulate alpha-synuclein aggregation
US7553639B2 (en) 2006-01-31 2009-06-30 Elan Pharma International Limited Alpha-synuclein kinase
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
US9375440B2 (en) 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
WO2008068024A2 (en) * 2006-12-06 2008-06-12 Universität Zürich Means and methods for isolating and determining novel targets for the treatment of neurodegenerative, neurological or neuropsychiatric disorders and compositions comprising the same
PT3067066T (en) 2007-02-23 2019-06-17 Univ California Prevention and treatment of synucleinopathic and amyloidogenic disease
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2118300T3 (en) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Prevention and treatment of synucleinopathic and amyloidogenic disease
US20110064721A1 (en) * 2007-07-12 2011-03-17 The Uab Research Foundation Cathepsin-d neuroprotection
US8110368B1 (en) * 2008-01-07 2012-02-07 The United States of America Department of Agriculture, as represented by the Secretary of Agriculture Synuclein gamma as a biomarker of obesity and obesity-related disorders
EP3026057A3 (en) 2009-03-09 2016-08-31 Ramot at Tel Aviv University Ltd. Compositions for prevention and treatment of neurodegenerative diseases
KR101101013B1 (en) * 2009-05-14 2011-12-29 아주대학교산학협력단 Screening methods for candidate materials having prophylactic or treating activity of amyloid-associated neurodegenerative diseases
RU2532525C2 (en) * 2012-12-10 2014-11-10 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Exogenic-induced animal model of alzheimer disease
US9241128B2 (en) 2013-02-14 2016-01-19 Warner Bros. Entertainment Inc. Video conversion technology
EP3224381B1 (en) 2014-11-25 2019-09-04 The Brigham and Women's Hospital, Inc. Method of identifying a person having a predisposition to or afflicted with a cardiometabolic disease
US10683552B2 (en) 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
KR101938956B1 (en) * 2016-05-31 2019-01-15 제주대학교 산학협력단 Neuronal-specific expression porcine thy1 gene promotor
WO2023246838A1 (en) * 2022-06-22 2023-12-28 Tsinghua University Disease model and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
WO1992020790A1 (en) 1991-05-15 1992-11-26 L'institut De Recherches Cliniques De Montreal Transgenic non-human animal carrying a non-infectious hiv genome

Also Published As

Publication number Publication date
US20030056231A1 (en) 2003-03-20
US7795495B2 (en) 2010-09-14
WO2001060794A2 (en) 2001-08-23
US20040128706A1 (en) 2004-07-01
WO2001060794A3 (en) 2002-01-24
US7276643B2 (en) 2007-10-02
US20080051337A1 (en) 2008-02-28
US7393994B2 (en) 2008-07-01

Similar Documents

Publication Publication Date Title
AU2001238612A1 (en) Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease
AUPR638101A0 (en) Composition and method for treatment of disease
AU2003246102A1 (en) Method of examining allergic disease and drug for treating the same
AU2001245751A1 (en) Method and device for skin cancer screening
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
AU2002329570A1 (en) Method of monitoring neuroprotective treatment
AU2002255898A1 (en) Methods and apparatus for treating diseased tissue
AU2001294794A1 (en) Method and apparatus for spectrophotometry of the eye
AU2002241323A1 (en) Acidic-wastewater treating material and method of treating acidic wastewater
AU2001257903A1 (en) Method for treatment of neurodegenerative diseases
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AU2003244132A1 (en) Method of examining allergic disaese and drug for treating the same
AU2002367145A1 (en) Remedies for anorexia or lifestyle-related diseases and method of screening the same
AU2002311845A1 (en) Methods of treating intestinal inflammation
AU2002326810A1 (en) Method of treating cancerous disease
AU2001283463A1 (en) Methods of diagnosis of cancer and screening for cancer modulators
AUPR644301A0 (en) Method and composition for treatment of cancer
AU2002305138A1 (en) Methods and materials for cancer treatment
AU2002228403A1 (en) Method of screening prion disease infection factor
AU2002342188A1 (en) Methods and compositions for treating flavivirus-mediated disease
GB0200943D0 (en) Rodenticide and method of screening
AU2002354206A1 (en) Method of screening drug
AU2002353915A1 (en) Methods and compositions for treating rotavirus-mediated disease
AU2002327160A1 (en) Method of treating spinal injury and remedy therefor
AUPR684101A0 (en) Method and apparatus for screening for immunoreactivity against disease